New Zealanders now have funded access to a global
standard of care treatment for a form of liver cancer,
Hepatocellular Carcinoma (HCC), which, unlike many other
cancers has a rapidly increasing rate of cancer mortality in
New Zealand[1],[2].
From 1 March 2025, TECENTRIQ
(atezolizumab) in combination with bevacizumab, will be
funded for eligible patients within the public system for
the first time.
Globally, liver cancer is one of the
least-survivable cancers, however, HCC – the main type of
liver cancer affecting adults – is treatable. The best
outcomes for patients are achievable with an early
diagnosis.
Provided by Roche, the funding
of TECENTRIQ will assist about 70 individuals diagnosed with
advanced HCC each year[3]. When used in combination with
bevacizumab, TECENTRIQ provides an alternative treatment
option for patients that may help them live well for
longer.
Roche New Zealand Country Medical
Director Kerryn Symons welcomed the funding of TECENTRIQ:
“We are pleased that this treatment, which has been the
standard of care in many countries for years, is now funded
for New Zealanders. With liver cancer being one of the few
cancers where mortality rates are on the rise, this
treatment can now be accessed by patients throughout
Aotearoa which is a great outcome.”
TECENTRIQ in
combination with bevacizumab has transformed HCC treatment
globally. These two treatments combine to treat the cancer
in two ways – TECENTRIQ is an immunotherapy that activates
the immune system to recognise, attack and destroy cancer
cells – and bevacizumab is anti-angiogenic, which slows
cancer growth by starving tumours of their blood
supply.
Advertisement – scroll to continue reading
With liver cancer being one of the
least-survivable cancers in New Zealand, Professor Ed Gane,
Hepatologist and Professor of Medicine at the University of
Auckland believes it is important for New Zealanders to have
access to better treatment options that are available
overseas.
“Patients require this treatment
combination when the HCC is unable to be removed by surgery
or has spread to other parts of the body. Clinical trial
results have shown that this treatment combination helped
patients to live for longer than other medicine[4]. Having
this option more readily accessible for New Zealanders is a
positive step for patients, their families and those that
care for them.”
It is not widely understood that the
main cause of HCC is chronic liver disease, which often goes
undetected and silently progresses to HCC. Both Hepatitis B
and Hepatitis C, diseases that are endemic in Aotearoa, can
progress to HCC5.
“More than 94,000 New Zealanders
are living with chronic viral hepatitis B of whom more than
200 will die each year from liver cancer. Every death is
preventable by earlier diagnosis, and follow-up. Hepatitis B
is responsible for almost half of HCC cases, while Hepatitis
C is responsible for approximately one-third[5],” says
Sarah Davey, Hepatitis Foundation of New Zealand Chief
Executive Officer.
“Our Māori and Pacific people
are disproportionately affected by HCC as these populations
have a higher prevalence of Hepatitis B and C, obesity and
diabetes, which are all underlying risk factors for chronic
liver disease. Māori patients have a lower survival rate
with 31% of Māori patients more likely to die of liver
cancer than non-Māori[6], and delayed diagnosis of HCC is
more common for Māori and Pacific people. This is due to
lower rates of diagnosis and management of the underlying
liver disease5. With 90% of chronic liver disease cases
being preventable[6], these are statistics that need to be
turned around,” says Davey.
The Hepatitis Foundation
provides freely accessible information and support as well
as a surveillance programme for people at risk of HCC.
“With proper monitoring and support, we can help to
prevent the progress of liver disease and reduce the rates
of HCC.” says Davey
Professor Gane adds: “All
adult Māori, Pasifika and Asian New Zealanders should be
tested for Hepatitis B. People most at risk of Hepatitis C
are those who have ever injected drugs, received a
transfusion before 1992, had a tattoo outside licenced
parlour, been in prison or received health care in
developing countries – and should be tested for the disease.
Diagnosis of hepatitis is a simple finger prick test and
treatment is free, safe and effective.”
Roche’s
holistic approach is focused on helping to stop and even
reverse the cycle of chronic liver disease and to one day
cure HCC.
“We believe that cutting-edge diagnosis
and treatment are key, along with working in partnership
with liver specialists, researchers and patient
organisations to raise awareness of the disease, prevent
progression and improve outcomes for patients,” adds
Symons.
Talk to your health professional about your
risk of liver disease. People living with hepatitis B should
contact The Hepatitis Foundation of New Zealand to find out
if they are eligible for HCC surveillance. If you have HCC,
ask your doctor if funded TECENTRIQ (atezolizumab) treatment
is suitable for you.
1. Te Whatu Ora
Health New Zealand Cancer Data Web Tool
https://tewhatuora.shinyapps.io/cancer-web-tool/
2.
Clough S et al. The past, present and future of liver cancer
control for Māori. NZ Med J 135(1567):91-100, 2022
3.
Pharmac. Decision to fund medicines for liver and ovarian
cancers, and to award Principal Supply Status for
bevacizumab to Vegzelma. 12 February 2025
https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-02-decision-to-fund-medicines-for-liver-and-ovarian-cancers-and-to-award-principal-supply-status-for-bevacizumab-to-vegzelma
4.
Tecentriqinf.pdf
https://www.medsafe.govt.nz/profs/datasheet/t/Tecentriqinf.pdf
5.
Increasing burden of advanced hepatocellular carcinoma in
New Zealand— the need for better surveillance. Schauer C
et al. NZMJ 22 May 2020, Vol 133 No 1515
6. Gurney J et
al. Disparities in cancer-specific survival between Māori
and non- Māori New Zealanders, 2007-2016
Additional
information about TECENTRIQ (atezolizumab)
Tecentriq®
(atezolizumab) 1200mg/20mL and 840mg/14ml and Tecentriq SC
(atezolizumab 1875 mg/15 mL solution for subcutaneous
injection) are Prescription Medicines used for early (has
not spread to other parts of the body) and advanced or
metastatic (has spread to other parts of the body) non-small
cell lung cancer (NSCLC), extensive stage small-cell lung
cancer, advanced or metastatic urothelial (bladder and
urinary system) cancer, advanced or metastatic triple
negative breast cancer and unresectable hepatocellular
carcinoma (HCC).
Ask your doctor if Tecentriq is right
for you.
Tecentriq is funded for patients with
unresectable HCC and locally advanced or metastatic NSCLC
that have previously received chemotherapy who meet defined
criteria. A prescription charge and other medical fees may
apply. Tecentriq is not funded for urothelial cancer, breast
cancer and other lung cancer indications. Tecentriq SC is
not funded for any indication. Ask your health professional
about the cost of the medicine and other fees that may
apply.
Use only as directed. If symptoms continue or
you have side effects, see your healthcare professional. For
more information about Tecentriq:
talk to your
health professional; or
visit medsafe.govt.nz for
Tecentriq Consumer Medicine Information; or visit
cancertreatments.co.nz or call Roche on 0800 276
243.
Tecentriq has risks and benefits.
Possible
common side effects include: loss of appetite; diarrhoea;
shortness of breath; itching of the skin; dry skin; rash;
nausea; fever; chills; vomiting; difficulty swallowing;
flu-like symptoms; nasal congestion; stomach, back, muscle,
bone, joint or throat pain; cough; sore throat; tiredness;
common cold; headaches; being short of breath when
exercising; urinary tract infection; lung infection;
dizziness, light-headedness, looking pale, fainting;
bleeding or bruising; mouth ulcers and/or cold sores;
constipation; numbness or weakness of the arms and legs;
high blood pressure; hair loss; a change in the way things
taste.
Tell your doctor if: you have immune system
problems such as Crohn’s disease, ulcerative colitis, or
lupus; you have inflammation of the lungs (pneumonitis); you
have liver problems, such as hepatitis; you have thyroid
problems; you are taking other medicines; you have allergies
to any other medicines, foods, preservatives or dyes; you
are pregnant or breastfeeding or plan to become pregnant or
breastfeed. Tell your doctor right away if you become
pregnant during treatment with Tecentriq.
Tell your
doctor immediately or go to your nearest Accident and
Emergency Centre if you notice any of the following:
inflammation of the lungs (new or worsening cough, shortness
of breath and chest pain); inflammation of the liver
(yellowing of skin or eyes, nausea, vomiting, bleeding or
bruising, dark urine, and stomach pain); inflammation of the
intestines (diarrhoea, blood in stools, and stomach pain);
inflammation of the thyroid, pituitary and adrenal glands
(tiredness, weight loss, weight gain, changes in mood or
behaviour, visual disturbances, increased sensitivity to
cold or heat, slow or rapid heart rate, hair loss,
constipation, headache, and dizziness); type 1 diabetes
mellitus (feeling more hungry or thirsty than usual, need to
urinate more often, weight loss, and feeling tired);
inflammation of the brain or spinal cord (neck stiffness,
headache, fever, chills, vomiting, eye sensitivity to light,
confusion and sleepiness); inflammation of the nerves
(muscle weakness, numbness or tingling in hands and feet);
inflammation of the pancreas (abdominal pain, nausea and
vomiting); inflammation of the heart muscle (shortness of
breath, feeling tired, irregular heart beat or chest pain);
inflammation of the sac surrounding the heart (chest pain,
difficulty and/or painful breathing, pounding/racing heart
beat, fainting and/or light-headedness, swelling of legs or
abdomen, pale and/or clammy skin); inflammation of the
kidneys (dark and/or frothy urine, high blood pressure,
swelling to face, feet, legs and hands; inflammation of
muscles (muscle pain or stiffness or skin rash); infusion
reactions (fever, chills, shortness of breath and flushing –
intravenous formulation only), local reaction at the
injection site (subcutaneous formulation only), excessive
activation of the immune system (fever, swollen lymph nodes,
skin rash, yellowing of skin and eyes, coughing, difficulty
breathing, vomiting, diarrhea headache, changes in vision,
weakness), paralysis of the facial muscles, inflammation of
the spinal cord (muscle weakness in the legs and arms,
numbness, problems with mobility, the bladder and bowel) or
any inflammation of the skin.
Panel dated 18 February
2025. All trademarks mentioned herein are protected by law.
Roche Products (New Zealand) Limited,
Auckland.
© Scoop Media



















Discussion about this post